Abstract:Hippocampus volumetry currently is the best-established imaging biomarker for AD. However, the effect of multicenter acquisition on measurements of hippocampus volume needs to be explicitly considered when it is applied in large clinical trials, for example by using mixed-effects models to take the clustering of data within centers into account. The marker needs further validation in respect of the underlying neurobiological substrate and potential confounds such as vascular disease, inflammation, hydrocephalus, and alcoholism, and with regard to clinical outcomes such as cognition but also to demographic and socioeconomic outcomes such as mortality and institutionalization. The use of hippocampus volumetry for risk stratification of predementia study samples will further increase with the availability of automated measurement approaches. An important step in this respect will be the development of a standard hippocampus tracing protocol that harmonizes the large range of presently available manual protocols. In the near future, regionally differentiated automated methods will become available together with an appropriate statistical model, such as multivariate analysis of deformation fields, or techniques such as cortical-thickness measurements that yield a meaningful metrics for the detection of treatment effects. More advanced imaging protocols, including DTI, DSI, and functional MRI, are presently being used in monocenter and first multicenter studies. In the future these techniques will be relevant for the risk stratification in phase IIa type studies (small proof-of-concept trials). By contrast, the application of the broader established structural imaging biomarkers, such as hippocampus volume, for risk stratification and as surrogate end point is already today part of many clinical trial protocols. However, clinical care will also be affected by these new technologies. Radiologic expert centers already offer “dementia screening” for well-off middle-aged people who undergo an MRI scan with subsequent automated, typically VBM-based analysis, and determination of z-score deviation from a matched control cohort. Next-generation scanner software will likely include radiologic expert systems for automated segmentation, deformation-based morphometry, and multivariate analysis of anatomic MRI scans for the detection of a typical AD pattern. As these developments will start to change medical practice, first for selected subject groups that can afford this type of screening but later eventually also for other cohorts, clinicians must become aware of the potentials and limitations of these technologies. It is decidedly unclear to date how a middle-aged cognitively intact subject with a seemingly AD-positive MRI scan should be clinically advised. There is no evidence for individual risk prediction and even less for specific treatments. Thus, the development of preclinical diagnostic imaging poses not only technical but also ethical problems that must be critically discussed on the basis of profound knowledge. From a neurobiological point of view, the main determinants of cognitive impairment in AD are the density of synapses and neurons in distributed cortical and subcortical networks. MRI-based measures of regional gray matter volume and associated multivariate analysis techniques of regional interactions of gray matter densities provide insight into the onset and temporal dynamics of cortical atrophy as a close proxy for regional neuronal loss and a basis of functional impairment in specific neuronal networks. From the clinical point of view, clinicians must bear in mind that patients do not suffer from hippocampus atrophy or disconnection but from memory impairment, and that dementia screening in asymptomatic subjects should not be used outside of clinical studies.

Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnestic mild cognitive impairment and Alzheimer's disease

Correlation of hippocampal volume and cognitive performances in patients with either mild cognitive impairment or Alzheimer's disease.

Study of Gray Matter Loss in Alzheimer's Disease Based on Automatic Voxel-based Morphometry

Combined cognitive assessment and automated MRI volumetry improves the diagnostic accuracy of detecting MCI due to Alzheimer's disease

Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study

Clinically feasible automated MRI volumetry of the brain as a prognostic marker in subjective and mild cognitive impairment

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment

Volumetric MRI and cognitive measures in Alzheimer disease

Automated Volumetric Software in Dementia: Help or Hindrance to the Neuroradiologist?

Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease

Regional MRI volumetry using NeuroQuant versus visual rating scales in patients with cognitive impairment and dementia

Analysis of Regional MRI Volumes and Thicknesses As Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease

Automated Brain MRI Volumetry Differentiates Early Stages of Alzheimer’s Disease From Normal Aging

Grey-matter volume as a potential feature for the classification of Alzheimer’s disease and mild cognitive impairment: an exploratory study

Longitudinal automated brain volumetry vs. expert visual assessment of atrophy progression on MRI is robust but caution is advised

Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer’s disease

IC–P–025: Regional Network Pattern of MRI Gray Matter Volume in Alzheimer's Dementia

Diagnostic utility of brain MRI volumetry in comparing traumatic brain injury, Alzheimer disease and behavioral variant frontotemporal dementia

An Automated Algorithm for the Computation of Brain Volume Change from Sequential MRIs Using an Iterative Principal Component Analysis and Its Evaluation for the Assessment of Whole-Brain Atrophy Rates in Patients with Probable Alzheimer's Disease.

P-020: Regional Gray Matter Reductions in Alzheimer’s Dementia and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer’s Disease Neuroimaging Initiative Using Voxel-Based Morphometry